Erectile Dysfunction Drugs Market: Market Segments: By Drug Type (Viagra (sildenafil citrate), Cialis (Tadalafil), Staxyn/Levitra (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (Alprostadil Cream) and Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Sales); By Mode of Administration (Oral Medications, Topical Medications , Injections and Others) and Region – Global Analysis of Market Size, Share & Trends for 2014 – 2020 and Forecasts to 2030
Erectile Dysfunction Drugs Market: Market Segments: By Drug Type (Viagra (sildenafil citrate), Cialis (Tadalafil), Staxyn/Levitra (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (Alprostadil Cream) and Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Sales); By Mode of Administration (Oral Medications, Topical Medications , Injections and Others) and Region – Global Analysis of Market Size, Share & Trends for 2014 – 2020 and Forecasts to 2030Product Overview
Inability to maintain and develop an erection for satisfactory sexual intercourse or activity refers to erectile dysfunction. The main causes of erectile dysfunction are high blood pressure, diabetes, high cholesterol, or depression. The symptoms of erectile dysfunction include trouble in maintaining an erection, difficulty in achieving an erection, and a reduced interest in sex. There are many medications available to treat erectile dysfunction which is commonly known as erectile dysfunction drugs.Market Highlights
Global Erectile Dysfunction Drugs Market is expected to project a notable CAGR of XX.X% in 2030.
Global Erectile Dysfunction Drugs Market to surpass USD XXXX million by 2030 from USD XXXX million in 2020 at a CAGR of XX.X% in the coming years, i.e., 2021-30. Due to the rising healthcare expenditure on sexual wellness, the demand for erectile dysfunction drugs is experiencing an escalating demand. The development of novel drug formulations is propelling the market growth further.Global Erectile Dysfunction Drugs Market: Segments
Viagra (sildenafil citrate) segment to grow with the highest CAGR during 2021-30
Global Erectile Dysfunction Drugs market is segmented by drugs type into Viagra (sildenafil citrate), Cialis (Tadalafil), Staxyn/Levitra (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (Alprostadil Cream), and Others. Viagra (sildenafil citrate), the segment held the largest market share of XX.X% in the year 2020 owing to its large number of sales worldwide over other drugs.Market Dynamics
Drivers
Increasing adoption of the sedentary lifestyle
The rising adoption of a sedentary lifestyle is resulting in the high growth of obesity, cardiovascular diseases, and diabetes, leading to complications such as erectile dysfunction. Poor lifestyle choices, smoking, alcoholism increases the risk of erectile dysfunction which in turn is boosting the overall growth of the erectile dysfunction drugs market. Besides, the factors such as the rise in the geriatric population and life expectancy are also driving the demand for erectile dysfunction drugs.Restraint
Side effects of drugs on health
The consumption of erectile dysfunction drugs may harm health which is likely to impede market growth. The common side effects include headache, nasal congestion, vision problems, dizziness, and diarrhea. Moreover, patients with cardiovascular disease have more risk as these drugs can cause a drop in blood pressure.
Global Erectile Dysfunction Drugs Market: Key Players
Apricus Biosciences Inc
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Bayer AG
Cristalia Dong-A Pharmaceutical Co. Ltd.
Produtos Quimicos Farmaceuticos Ltd.
Eli Lilly and Company
Pfizer, Inc.
GlaxoSmithKline Plc
S.K. Chemicals Co. Ltd.
Meda Pharmaceuticals, Inc
Vivus, Inc.
Metuchen Pharmaceuticals LLC
Other Prominent Players
Global Erectile Dysfunction Drugs Market: Regions
Global Erectile Dysfunction Drugs Market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, Asia Pacific, and the Middle East, and Africa. Global Erectile Dysfunction Drugs Market in North America held the largest market share of XX.X% in the year 2020. North America will continue to dominate the global Erectile Dysfunction Drugs market owing to rising healthcare expenditure, growing geriatric population, and high life expectancy. Also, increasing consumer awareness and education in the region is anticipated to fuel the growth of the market.
Inability to maintain and develop an erection for satisfactory sexual intercourse or activity refers to erectile dysfunction. The main causes of erectile dysfunction are high blood pressure, diabetes, high cholesterol, or depression. The symptoms of erectile dysfunction include trouble in maintaining an erection, difficulty in achieving an erection, and a reduced interest in sex. There are many medications available to treat erectile dysfunction which is commonly known as erectile dysfunction drugs.Market Highlights
Global Erectile Dysfunction Drugs Market is expected to project a notable CAGR of XX.X% in 2030.
Global Erectile Dysfunction Drugs Market to surpass USD XXXX million by 2030 from USD XXXX million in 2020 at a CAGR of XX.X% in the coming years, i.e., 2021-30. Due to the rising healthcare expenditure on sexual wellness, the demand for erectile dysfunction drugs is experiencing an escalating demand. The development of novel drug formulations is propelling the market growth further.Global Erectile Dysfunction Drugs Market: Segments
Viagra (sildenafil citrate) segment to grow with the highest CAGR during 2021-30
Global Erectile Dysfunction Drugs market is segmented by drugs type into Viagra (sildenafil citrate), Cialis (Tadalafil), Staxyn/Levitra (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (Alprostadil Cream), and Others. Viagra (sildenafil citrate), the segment held the largest market share of XX.X% in the year 2020 owing to its large number of sales worldwide over other drugs.Market Dynamics
Drivers
Increasing adoption of the sedentary lifestyle
The rising adoption of a sedentary lifestyle is resulting in the high growth of obesity, cardiovascular diseases, and diabetes, leading to complications such as erectile dysfunction. Poor lifestyle choices, smoking, alcoholism increases the risk of erectile dysfunction which in turn is boosting the overall growth of the erectile dysfunction drugs market. Besides, the factors such as the rise in the geriatric population and life expectancy are also driving the demand for erectile dysfunction drugs.Restraint
Side effects of drugs on health
The consumption of erectile dysfunction drugs may harm health which is likely to impede market growth. The common side effects include headache, nasal congestion, vision problems, dizziness, and diarrhea. Moreover, patients with cardiovascular disease have more risk as these drugs can cause a drop in blood pressure.
Global Erectile Dysfunction Drugs Market: Key Players
Apricus Biosciences Inc
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Bayer AG
Cristalia Dong-A Pharmaceutical Co. Ltd.
Produtos Quimicos Farmaceuticos Ltd.
Eli Lilly and Company
Pfizer, Inc.
GlaxoSmithKline Plc
S.K. Chemicals Co. Ltd.
Meda Pharmaceuticals, Inc
Vivus, Inc.
Metuchen Pharmaceuticals LLC
Other Prominent Players
Global Erectile Dysfunction Drugs Market: Regions
Global Erectile Dysfunction Drugs Market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, Asia Pacific, and the Middle East, and Africa. Global Erectile Dysfunction Drugs Market in North America held the largest market share of XX.X% in the year 2020. North America will continue to dominate the global Erectile Dysfunction Drugs market owing to rising healthcare expenditure, growing geriatric population, and high life expectancy. Also, increasing consumer awareness and education in the region is anticipated to fuel the growth of the market.
1. EXECUTIVE SUMMARY
2. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Drugs Type: Market Share (2020-2030F)
12.2.1. Viagra (sildenafil citrate), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Cialis(tadalfil), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Staxyn/Levitra (vardenafil), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.4. Zydena (udenafil), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.5. Vitaros (Alprostadil Cream) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.6. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Distribution Channel: Market Share (2020-2030F)
12.3.1. Hospital Pharmacies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Retail Pharmacies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Online Sales, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By Mode of Administration: Market Share (2020-2030F)
12.4.1. Oral medications, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Topical Medications, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Injections, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030
12.4.4. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030
13. COMPANY PROFILE
13.1. Apricus Biosciences Inc
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Bayer AG
13.3. Cristalia Dong-A Pharmaceutical Co. Ltd.
13.4. Produtos Quimicos Farmaceuticos Ltd.
13.5. Eli Lilly and Company
13.6. Pfizer, Inc.
13.7. GlaxoSmithKline Plc
13.8. S.K. Chemicals Co. Ltd.
13.9. Meda Pharmaceuticals, Inc
13.10. Vivus, Inc.
13.11. Metuchen Pharmaceuticals LLC
13.12. Other Prominent Players
Consultant Recommendation
The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
2. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Drugs Type: Market Share (2020-2030F)
12.2.1. Viagra (sildenafil citrate), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Cialis(tadalfil), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Staxyn/Levitra (vardenafil), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.4. Zydena (udenafil), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.5. Vitaros (Alprostadil Cream) By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.6. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Distribution Channel: Market Share (2020-2030F)
12.3.1. Hospital Pharmacies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Retail Pharmacies, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Online Sales, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By Mode of Administration: Market Share (2020-2030F)
12.4.1. Oral medications, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Topical Medications, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Injections, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030
12.4.4. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030
13. COMPANY PROFILE
13.1. Apricus Biosciences Inc
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Bayer AG
13.3. Cristalia Dong-A Pharmaceutical Co. Ltd.
13.4. Produtos Quimicos Farmaceuticos Ltd.
13.5. Eli Lilly and Company
13.6. Pfizer, Inc.
13.7. GlaxoSmithKline Plc
13.8. S.K. Chemicals Co. Ltd.
13.9. Meda Pharmaceuticals, Inc
13.10. Vivus, Inc.
13.11. Metuchen Pharmaceuticals LLC
13.12. Other Prominent Players
Consultant Recommendation
The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
